Search Results 161-170 of 16462 for monoclonal antibody

1. Biological therapy for cancer - Mayo Clinic

   Gene therapy; Immune checkpoint modulators; Immunoconjugates; Monoclonal antibodies; Oncolytic virus therapy; Targeted drug therapy. Many types of biological ...

2. Oncology (Medical) - Clinical trials - Mayo Clinic

   Bevacizumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Immunotherapy with monoclonal antibodies, such as ...

3. Covid Queries: Do I need the vaccine if I've had COVID-19? - Mayo Clinic News Network

   Monoclonal antibodies are proteins made in a laboratory that mimic the body's immune response, and they can keep you from developing a robust response to the ...

4. Mayo Clinic Q&A - Dr. Yi LIn - Multiple myeloma

   We also have since then monoclonal antibody treatments. So, these are again drugs that can be given IV that target certain markers that can show up on plasma ...

5. Publications - Sarosh R. Irani, B.M.B.Ch., D.Phil. - Mayo Clinic

   Peripherally-derived LGI1-reactive monoclonal antibodies cause epileptic seizures in vivo. ... Magnetic Resonance Imaging Characteristics of LGI1-Antibody and ...

6. A Study of the Expression and Frequency of Tissue Biomarker Mutations in Breast Cancer that is Resistant or Refractory to Treatment with Trastuzumab and/or Pertuzumab - Mayo Clinic

   ... monoclonal antibody therapy, such as trastuzumab emtansine (T-DM1) and/or pertuzumab. Participation eligibility. Participant eligibility includes age, gender ...

7. Belantamab mafodotin-blmf (intravenous route) - Mayo Clinic

   ... monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent) that did not work well. This medicine is available only under a restricted ...

8. Tolerability, safety and deep response found in cevostamab phase 1 trial - Mayo Clinic

   Stewart and colleagues in a February 2019 issue of Blood Cancer Journal, investigators studied a naked antibody, the more commonly used type of monoclonal ...

9. A First-in-Human, Phase 1 Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BJ-005 in Patients With Advanced Solid Tumor or Lymphoma - Mayo Clinic

   BJ-005 is a recombinant bifunctional molecule, composed of a humanized anti-PD-L1 IgG1 monoclonal antibody (mAb) fused with a portion of the extracellular ...

10. Publications - Melissa R. Snyder, Ph.D. - Mayo Clinic

    Lack of observed interference by therapeutic monoclonal antibodies ... Monoclonal antibody therapeutics as potential interferences on protein electrophoresis and ...